Price
Financials
Standalone, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 24.30 | 26.66 | 22.82 | 30.84 | 39.39 | 33.08 | 39.14 | 20.01 | 3.06 | 2.20 | -0.13 | 1.23 |
| Expenses | 23.25 | 25.60 | 26.81 | 29.04 | 38.60 | 32.81 | 35.73 | 20.51 | 7.06 | 2.95 | 1.99 | 2.62 |
| Operating Profit | 1.05 | 1.06 | -3.99 | 1.80 | 0.79 | 0.27 | 3.41 | -0.50 | -4.00 | -0.75 | -2.12 | -1.39 |
| OPM % | 4.32% | 3.98% | -17.48% | 5.84% | 2.01% | 0.82% | 8.71% | -2.50% | -130.72% | -34.09% | -113.01% | |
| Other Income | 0.08 | 0.00 | -8.76 | 0.00 | 1.95 | 8.91 | -21.52 | -20.44 | 0.01 | 0.02 | -0.42 | -0.38 |
| Interest | 0.56 | 0.44 | 0.56 | 0.87 | 1.24 | 0.47 | 0.11 | 0.03 | 0.12 | 0.11 | 0.13 | 0.14 |
| Depreciation | 2.68 | 2.68 | 2.66 | 2.79 | 2.81 | 2.80 | 3.90 | 1.57 | 1.57 | 1.57 | 1.31 | 1.57 |
| Profit before tax | -2.11 | -2.06 | -15.97 | -1.86 | -1.31 | 5.91 | -22.12 | -22.54 | -5.68 | -2.41 | -3.98 | -3.48 |
| Tax % | -99.05% | -29.61% | -4.20% | 46.77% | 146.56% | 7.11% | -35.40% | -6.30% | 10.04% | 5.81% | 4.77% | 3.16% |
| Net Profit | -0.02 | -1.46 | -15.30 | -2.73 | -3.23 | 5.49 | -14.29 | -21.12 | -6.25 | -2.55 | -4.16 | -3.58 |
| EPS in Rs | -0.00 | -0.29 | -3.05 | -0.54 | -0.64 | 1.10 | -2.85 | -4.22 | -1.25 | -0.51 | -0.83 | -0.71 |
| Mar 2016 1m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 199 | 244 | 170 | 167 | 201 | 137 | 130 | 104 | 142 | 25 | 6 |
| Expenses | 0 | 153 | 202 | 158 | 137 | 154 | 120 | 136 | 102 | 136 | 32 | 15 |
| Operating Profit | 0 | 46 | 41 | 11 | 30 | 47 | 16 | -6 | 2 | 6 | -7 | -8 |
| OPM % | 23% | 17% | 7% | 18% | 24% | 12% | -4.9% | 2.1% | 4.5% | -29% | -130% | |
| Other Income | 0 | -24 | 3 | 0 | 0 | 0 | -8 | -18 | -9 | -11 | -21 | -1 |
| Interest | 0 | 12 | 11 | 8 | 8 | 2 | 0 | 4 | 2 | 3 | 0 | 0 |
| Depreciation | 0 | 8 | 18 | 19 | 17 | 16 | 15 | 13 | 11 | 12 | 6 | 6 |
| Profit before tax | 0 | 2 | 15 | -16 | 5 | 30 | -6 | -42 | -19 | -19 | -35 | -16 |
| Tax % | -10% | 19% | -25% | 23% | 23% | -13% | -9% | 14% | -24% | -2% | ||
| Net Profit | 0 | 2 | 12 | -12 | 4 | 23 | -5 | -39 | -22 | -15 | -34 | -17 |
| EPS in Rs | 5.40 | -5.26 | 0.89 | 5.60 | -1.31 | -7.71 | -4.34 | -2.95 | -6.80 | -3.30 | ||
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | -24% | 0% | 0% | 0% | 0% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | -34% | -42% | -95% | ||
| Compounded Profit Growth | % | % | 10% | -547% | ||
| Stock Price CAGR | % | -41% | -40% | -51% | ||
| Return on Equity | 1% | -8% | -10% | -20% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 23 | 23 | 41 | 41 | 50 | 50 | 50 | 50 | 50 |
| Reserves | 0 | 75 | 94 | 82 | 101 | 118 | 108 | 68 | 47 | 34 | -0 |
| Borrowings | 0 | 116 | 107 | 85 | 48 | 19 | 20 | 22 | 22 | 2 | 10 |
| Other Liabilities | 0 | 37 | 63 | 69 | 42 | 29 | 31 | 24 | 32 | 16 | 7 |
| Total Liabilities | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
| Fixed Assets | 0 | 119 | 170 | 162 | 152 | 143 | 137 | 119 | 110 | 68 | 55 |
| CWIP | 0 | 30 | 7 | 7 | 0 | 0 | 5 | 5 | 3 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 0 | 80 | 110 | 90 | 80 | 65 | 67 | 40 | 39 | 33 | 12 |
| Total Assets | 0 | 228 | 287 | 258 | 232 | 208 | 209 | 164 | 151 | 102 | 67 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -3 | 40 | 41 | 14 | 41 | 9 | -17 | 2 | -3 | -8 |
| Cash from Investing Activity | 0 | 0 | -44 | -7 | -2 | -4 | -3 | 11 | -0 | 8 | 0 |
| Cash from Financing Activity | 0 | 0 | 4 | -33 | -10 | -36 | -0 | -4 | -2 | -6 | 7 |
| Net Cash Flow | 0 | -3 | 0 | -0 | 2 | 1 | 6 | -10 | -0 | -0 | 0 |
| Free Cash Flow | 0 | -5 | -6 | 29 | 13 | 35 | 12 | -12 | 0 | 5 | -7 |
| CFO/OP | -6% | 103% | 397% | 46% | 87% | 73% | 273% | 96% | -45% | 105% |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 64 | 63 | 62 | 45 | 27 | 50 | 7 | 13 | 4 | 1 | |
| Inventory Days | 93 | 90 | 90 | 101 | 56 | 46 | 48 | 92 | 84 | 28 | |
| Days Payable | 71 | 102 | 170 | 130 | 41 | 68 | 32 | 68 | 35 | 33 | |
| Cash Conversion Cycle | 87 | 51 | -18 | 16 | 42 | 28 | 22 | 37 | 53 | -4 | |
| Working Capital Days | 15 | -1 | -52 | -13 | 35 | 12 | -17 | -44 | 37 | -102 | |
| ROCE % | 42% | 13% | -4% | 7% | 17% | 1% | -12% | -6% | -1% | -18% |
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% | 53.65% |
| FIIs | 0.00% | 0.00% | 0.01% | 0.12% | 0.00% | 0.01% | 0.00% | 0.00% | 0.47% | 0.00% | 0.00% | 0.00% |
| Public | 46.34% | 46.34% | 46.33% | 46.23% | 46.34% | 46.32% | 46.35% | 46.35% | 45.88% | 46.35% | 46.34% | 46.35% |
| No. of Shareholders | 28,031 | 27,770 | 27,161 | 27,615 | 27,217 | 27,968 | 27,272 | 27,188 | 28,115 | 28,656 | 28,120 | 27,702 |
Fundamentals
Market Cap₹ 28.1 Cr.
Current Price₹ 5.60
Book Value₹ 9.90
ROCE-18.2 %
ROE-19.7 %
Dividend Yield0.00 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)-95%
Compounded Profit Growth (TTM)-547%
Standalone figures.
Valuation
Market capRs 28 Cr
Enterprise valueRs 37 Cr
Price to book0.57x
Price to sales4.41x
EV / sales5.83x
Earnings yield-58.95%
P/B, 3-year average0.79x
P/B, 5-year average0.92x
Profitability
Operating margin (excl. other income)-29.20%
Operating margin (incl. other income)-112.05%
EBITDA margin-141.98%
Pre-tax margin-244.50%
Net profit margin-260.06%
Net margin, latest quarter-291.06%
ROE-51.14%
ROCE-47.09%
ROA-40.56%
ROE, 3-year average-29.24%
ROCE, 3-year average-25.51%
ROA, 3-year average-22.02%
ROE, 5-year average-23.81%
ROCE, 5-year average-20.78%
ROA, 5-year average-17.87%
ROIC (approx.)-25.27%
Tax rate1.50%
Other income / net worth-41.98%
Growth
Sales growth (latest year)-82.35%
Sales CAGR, 3 years-42.10%
Sales CAGR, 5 years-34.03%
Sales growth QoQ-1046.15%
Sales growth YoY (latest quarter)-93.85%
Per share
EPS (TTM)Rs -3.30
EPS (latest year)Rs -6.80
EPS (latest quarter)Rs -0.71
EPS, 3-year averageRs -4.88
EPS, 5-year averageRs -4.63
Book value per shareRs 9.90
Sales per shareRs 1.27
Cash flow per shareRs -1.53
Free cash flow per shareRs -1.40
Dividend per share, 5-year averageRs 0.25
Efficiency
Asset turnover0.38x
Fixed asset turnover0.46x
Inventory turnover15.32x
Inventory days24 days
Debtor days1 days
Debtors turnover628.50x
Creditor days33 days
Cash conversion cycle-4 days
Working capital days-102 days
Leverage
Total debtRs 10 Cr
Cash and bankRs 1 Cr
Net debtRs 9 Cr
Debt to equity0.20x
Interest coverage-30.10x
Owners' fund to total sources74.54%
Debt to assets14.65%
Cash flow
Cash from Operating Activity (latest year)Rs -8 Cr
Cash from Investing Activity (latest year)Rs 0 Cr
Cash from Financing Activity (latest year)Rs 7 Cr
Net Cash Flow (latest year)Rs 0 Cr
Free cash flow (latest year)Rs -7 Cr
FCFE (approx.: FCF + change in debt)Rs 1 Cr
Statement figures
Net sales (TTM)Rs 6 Cr
Net sales (latest year)Rs 25 Cr
Sales (latest quarter)Rs 1 Cr
Operating profit excl. other income (latest year)Rs -7 Cr
Operating profit (latest quarter)Rs -1 Cr
Other income (TTM)Rs -1 Cr
EBITDA (TTM)Rs -9 Cr
PBDT (TTM)Rs -10 Cr
Profit before tax (TTM)Rs -16 Cr
Tax (latest year)Rs -1 Cr
Net profit (TTM)Rs -17 Cr
Net profit (latest year)Rs -34 Cr
Net profit (latest quarter)Rs -4 Cr
Depreciation (TTM)Rs 6 Cr
Depreciation (latest quarter)Rs 2 Cr
Interest (TTM)Rs 0 Cr
Cost of goods sold (latest year)Rs 28 Cr
Total expenditure (latest year)Rs 32 Cr
Total income (latest year)Rs 4 Cr
Share capitalRs 50 Cr
ReservesRs -0 Cr
Shareholders' fundsRs 50 Cr
Total assetsRs 67 Cr
Net blockRs 55 Cr
ReceivablesRs 0 Cr
InventoryRs 2 Cr
Other liabilitiesRs 7 Cr
Shares outstanding (crore)5.01
Ownership
Promoter holding53.65% (+0.00 in a year)
Computed by MarketFriction from the standalone statements. Returns use average balances.
P/B 0.57 is at the 7th percentile (median 1.20).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
| Period | LASA | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | -16.2% | -2.8% | -13.4 pts |
| 1 month | -24.4% | -6.8% | -17.6 pts |
| 3 months | -24.7% | -7.6% | -17.1 pts |
| 6 months | -28.3% | +0.4% | -28.7 pts |
| 1 year | -56.0% | -9.9% | -46.1 pts |
| 2 years | -82.7% | -13.6% | -69.2 pts |
| 3 years | -78.6% | +14.2% | -92.8 pts |
| 5 years | -92.4% | +27.9% | -120.3 pts |
Red flags
F-score 2 of 8| explain | Debt up, profit down Borrowings up 358% while net profit fell in 2026 |
| look | Repeated losses Net loss in each of the last two years |
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Latest quarter
Jun 2026Sales ₹1 Cr -93.9% vs Jun 2025.
Net loss ₹4 Cr.
Against our estimate for Jun 2026: sales -89.8%, profit +73.1% beat. Our estimate for Sep 2026: sales Rs 2 Cr, profit Rs -3 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2024-09-20 | Annual General Meeting | |
| 2023-09-20 | Annual General Meeting | |
| 2022-09-16 | Annual General Meeting/Dividend - Re 0.25 Per Share | |
| 2021-09-15 | Annual General Meeting/Dividend - Rs 0.25 Per Share | |
| 2020-09-17 | Annual General Meeting | |
| 2019-09-19 | Annual General Meeting | |
| 2018-09-17 | Annual General Meeting |
| Date | Type | What it says |
|---|---|---|
| 2026-10-01 | Shareholder meeting | Voting results. |
| 2026-09-30 | Shareholder meeting | Proceedings of Annual General Meeting held on September 30, 2026 |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Company has failed to pay Annual listing feeEPS in the scrip is zero (4 trailing quarters)Less than 100 unique PAN traded in previous 30 days
Quick answers
What is the market cap of Lasa Supergenerics Ltd?
Lasa Supergenerics Ltd (LASA) has a market capitalisation of Rs 28.1 Cr. at the 2026-09-28 close.
What were Lasa Supergenerics Ltd's latest quarterly results?
In the Jun 2026 quarter, Lasa Supergenerics Ltd sales was Rs 1 Cr (-93.9% vs Jun 2025) with a net loss of Rs 4 Cr.
What is the 52-week high and low of Lasa Supergenerics Ltd?
The 52-week high is Rs 14.08 and the 52-week low is Rs 5.60.